Amicus Therapeutics (FOLD) 6.71 $FOLD
Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics
PR Newswire - Fri Sep 12, 7:40AM CDT
On Thursday, September 11, 2014, the NASDAQ Composite ended at 4,591.81, up 0.12%, the Dow Jones Industrial Average finished the day 0.12% lower at 17,049.00, and the S&P 500 closed at 1,997.45, up 0.09%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 741.83, down 0.33%, while the index has advanced 5.97% in the last one month. Investor-Edge has initiated coverage on the following equities: Exelixis Inc. (NASDAQ: EXEL), Arena Pharmaceuticals Inc. (NASDAQ: ARNA), Novavax Inc. (NASDAQ: NVAX), Dendreon Corporation (NASDAQ: DNDN), and Amicus Therapeutics Inc. (NASDAQ: FOLD). Free research on these five companies can be accessed at:
Why Amicus Therapeutics (FOLD) Stock Might be a Great Pick - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Sep 03, 7:36AM CDT
Amicus Therapeutics (FOLD) is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective. It currently has a Zacks Industry Rank of 72 out of more than 250 industries.
Amicus Therapeutics (FOLD) Stock Rises on High Volume
at The Street - Thu Aug 28, 11:40AM CDT
Amicus Therapeutics (FOLD) nearly touched a 52-week high of $7.40 on Thursday as the stock continued to rise on high volume.
The Zacks Analyst Blog Highlights: RadioShack, Amicus Therapeutics, Sanofi, Shire and Gilead Sciences
PR Newswire - Thu Aug 28, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the RadioShack Corp. (NYSE:RSH-Free Report), Amicus Therapeutics (Nasdaq:FOLD-Free Report), Sanofi (NYSE:SNY-Free Report), Shire (Nasdaq:SHPG-Free Report) and Gilead Sciences Inc. (Nasdaq:GILD-Free Report).
Biotech Stock Roundup: Biotechs Surge on InterMune Acquisition Deal, Focus on More M&As - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Aug 27, 9:32AM CDT
Roche's agreement to acquire InterMune has raised hopes for more such deals in the biotech sector.
Amicus Therapeutics Hits 52-Week High on Migalastat Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 27, 8:49AM CDT
Shares of Amicus Therapeutics (FOLD) hit a 52-week high of $6.28 during the trading session on Aug 26.
Five Billionaire-Owned Biotech Stocks You Could Acquire for 100%
at The Street - Mon Aug 25, 1:18PM CDT
These five stocks all have the potential to be acquired for a 100% premium or more, and each are heavily owned by a top hedge fund or billionaire...
Clinical Trial Results, Change of Corporate Name, New Products, and Completion of Acquisition - Research Reports on GSK, Amicus, WellPoint, IDEXX and Endo
PR Newswire - Mon Aug 25, 7:40AM CDT
Today, Analysts Review released its research reports regarding GlaxoSmithKline PLC (NYSE: GSK), Amicus Therapeutics, Inc. (NASDAQ: FOLD), WellPoint Inc. (NYSE: WLP), IDEXX Laboratories, Inc. (NASDAQ: IDXX) and Endo International PLC (NASDAQ: ENDP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5933-100free.
Trade-Ideas: Amicus Therapeutics (FOLD) Is Today's Strong On High Relative Volume Stock
at The Street - Fri Aug 22, 1:14PM CDT
Trade-Ideas LLC identified Amicus Therapeutics (FOLD) as a strong on high relative volume candidate
Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day
PR Newswire - Fri Aug 22, 9:20AM CDT
Zacks Equity Research highlights Epizyme (Nasdaq:EPZM-Free Report) as the Bull of the Day and Panera (Nasdaq
NRA-Free Report) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Amicus Therapeutics (Nasdaq:FOLD-Free Report), Sanofi (NYSE:SNY-Free Report) and Shire (Nasdaq:SHPG-Free Report).
Amicus Therapeutics (FOLD) Soars on Fabry Drug Trial Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 21, 3:55PM CDT
Amicus Therapeutics (FOLD) announced positive data from its second phase III study on migalastat.
Amicus Therapeutics (FOLD) Worth Watching: Stock Rises 20.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Aug 21, 8:39AM CDT
Amicus Therapeutics, Inc. (FOLD) was a big mover last session, as its shares rose over 20% on the day.
Can the Rally in Amicus Therapeutics (FOLD) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Aug 21, 8:03AM CDT
Can the Rally in Amicus Therapeutics (FOLD) Shares Continue?
SmarTrend Watching for Potential Pullback in Shares of Amicus Therapeutics After 20.35% Gain
Comtex SmarTrend(R) - Wed Aug 20, 4:00PM CDT
Amicus Therapeutics (NASDAQ:FOLD) traded in a range yesterday that spanned from a low of $5.02 to a high of $5.99. Yesterday, the shares gained 20.4%, which took the trading range above the 3-day high of $4.70 on volume of 33.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Why Amicus Therapeutics (FOLD) Stock Hit a One-Year High Today
at The Street - Wed Aug 20, 9:29AM CDT
Amicus Therapeutics (FOLD) surged to a 52-week high on Wednesday after the company announced its potential Fabry disease treatment drug migalastat met its primary endpoints in a late-stage study.
Why Amicus Therapeutics, Inc. Stock Is Soaring Today
George Budwell, The Motley Fool - Motley Fool - Wed Aug 20, 9:12AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Amicus Therapeutics , a clinical-stage...
Amicus Therapeutics Has Returned 111.6% Since SmarTrend Recommendation (FOLD)
Comtex SmarTrend(R) - Wed Aug 20, 9:10AM CDT
SmarTrend identified an Uptrend for Amicus Therapeutics (NASDAQ:FOLD) on May 30th, 2014 at $2.42. In approximately 3 months, Amicus Therapeutics has returned 111.57% as of today's recent price of $5.12.
Yes, Call it a Comeback: Amicus Fabry Drug Posts Big Study Win
at The Street - Wed Aug 20, 5:01AM CDT
Based on the positive study results, Amicus intends to seek European approval for migalastat early next year.
Amicus Therapeutics Announces Positive Phase 3 Data From Fabry Monotherapy Study 012
GlobeNewswire - Wed Aug 20, 5:00AM CDT
Migalastat Successfully Meets Both Co-Primary Endpoints of Comparability to Enzyme Replacement Therapy (ERT) on Both Key Measures of Kidney Function
Pre-Market Review on Biotech Equities -- Exelixis, Novavax, Achillion Pharma, XOMA, and Amicus Therapeutics
PR Newswire - Wed Aug 13, 7:50AM CDT
On Tuesday, August 12, 2014, the NASDAQ Composite ended at 4,389.25, down 0.27%, the Dow Jones Industrial Average finished the session at 16,560.54, down 0.06% and the S&P 500 closed at 1,933.75, down 0.16%. During the trading session, seven out of ten sectors finished on a lower note. The S&P 500 Health Care Sector Index ended the day 0.14% lower at 699.06, and the index has declined 1.94% in the previous one month. Investor-Edge has initiated coverage on the following equities: Exelixis Inc. (NASDAQ: EXEL), Novavax Inc. (NASDAQ: NVAX), Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), XOMA Corp. (NASDAQ: XOMA), and Amicus Therapeutics Inc. (NASDAQ: FOLD). Free research on these five companies can be accessed at:
Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics
PR Newswire - Fri Sep 12, 7:40AM CDT
On Thursday, September 11, 2014, the NASDAQ Composite ended at 4,591.81, up 0.12%, the Dow Jones Industrial Average finished the day 0.12% lower at 17,049.00, and the S&P 500 closed at 1,997.45, up 0.09%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 741.83, down 0.33%, while the index has advanced 5.97% in the last one month. Investor-Edge has initiated coverage on the following equities: Exelixis Inc. (NASDAQ: EXEL), Arena Pharmaceuticals Inc. (NASDAQ: ARNA), Novavax Inc. (NASDAQ: NVAX), Dendreon Corporation (NASDAQ: DNDN), and Amicus Therapeutics Inc. (NASDAQ: FOLD). Free research on these five companies can be accessed at:
Why Amicus Therapeutics (FOLD) Stock Might be a Great Pick - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Sep 03, 7:36AM CDT
Amicus Therapeutics (FOLD) is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective. It currently has a Zacks Industry Rank of 72 out of more than 250 industries.
Amicus Therapeutics (FOLD) Stock Rises on High Volume
at The Street - Thu Aug 28, 11:40AM CDT
Amicus Therapeutics (FOLD) nearly touched a 52-week high of $7.40 on Thursday as the stock continued to rise on high volume.
The Zacks Analyst Blog Highlights: RadioShack, Amicus Therapeutics, Sanofi, Shire and Gilead Sciences
PR Newswire - Thu Aug 28, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the RadioShack Corp. (NYSE:RSH-Free Report), Amicus Therapeutics (Nasdaq:FOLD-Free Report), Sanofi (NYSE:SNY-Free Report), Shire (Nasdaq:SHPG-Free Report) and Gilead Sciences Inc. (Nasdaq:GILD-Free Report).
Biotech Stock Roundup: Biotechs Surge on InterMune Acquisition Deal, Focus on More M&As - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Aug 27, 9:32AM CDT
Roche's agreement to acquire InterMune has raised hopes for more such deals in the biotech sector.
Amicus Therapeutics Hits 52-Week High on Migalastat Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 27, 8:49AM CDT
Shares of Amicus Therapeutics (FOLD) hit a 52-week high of $6.28 during the trading session on Aug 26.
Five Billionaire-Owned Biotech Stocks You Could Acquire for 100%
at The Street - Mon Aug 25, 1:18PM CDT
These five stocks all have the potential to be acquired for a 100% premium or more, and each are heavily owned by a top hedge fund or billionaire...
Clinical Trial Results, Change of Corporate Name, New Products, and Completion of Acquisition - Research Reports on GSK, Amicus, WellPoint, IDEXX and Endo
PR Newswire - Mon Aug 25, 7:40AM CDT
Today, Analysts Review released its research reports regarding GlaxoSmithKline PLC (NYSE: GSK), Amicus Therapeutics, Inc. (NASDAQ: FOLD), WellPoint Inc. (NYSE: WLP), IDEXX Laboratories, Inc. (NASDAQ: IDXX) and Endo International PLC (NASDAQ: ENDP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5933-100free.
Trade-Ideas: Amicus Therapeutics (FOLD) Is Today's Strong On High Relative Volume Stock
at The Street - Fri Aug 22, 1:14PM CDT
Trade-Ideas LLC identified Amicus Therapeutics (FOLD) as a strong on high relative volume candidate
Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day
PR Newswire - Fri Aug 22, 9:20AM CDT
Zacks Equity Research highlights Epizyme (Nasdaq:EPZM-Free Report) as the Bull of the Day and Panera (Nasdaq
NRA-Free Report) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Amicus Therapeutics (Nasdaq:FOLD-Free Report), Sanofi (NYSE:SNY-Free Report) and Shire (Nasdaq:SHPG-Free Report). Amicus Therapeutics (FOLD) Soars on Fabry Drug Trial Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 21, 3:55PM CDT
Amicus Therapeutics (FOLD) announced positive data from its second phase III study on migalastat.
Amicus Therapeutics (FOLD) Worth Watching: Stock Rises 20.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Aug 21, 8:39AM CDT
Amicus Therapeutics, Inc. (FOLD) was a big mover last session, as its shares rose over 20% on the day.
Can the Rally in Amicus Therapeutics (FOLD) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Aug 21, 8:03AM CDT
Can the Rally in Amicus Therapeutics (FOLD) Shares Continue?
SmarTrend Watching for Potential Pullback in Shares of Amicus Therapeutics After 20.35% Gain
Comtex SmarTrend(R) - Wed Aug 20, 4:00PM CDT
Amicus Therapeutics (NASDAQ:FOLD) traded in a range yesterday that spanned from a low of $5.02 to a high of $5.99. Yesterday, the shares gained 20.4%, which took the trading range above the 3-day high of $4.70 on volume of 33.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Why Amicus Therapeutics (FOLD) Stock Hit a One-Year High Today
at The Street - Wed Aug 20, 9:29AM CDT
Amicus Therapeutics (FOLD) surged to a 52-week high on Wednesday after the company announced its potential Fabry disease treatment drug migalastat met its primary endpoints in a late-stage study.
Why Amicus Therapeutics, Inc. Stock Is Soaring Today
George Budwell, The Motley Fool - Motley Fool - Wed Aug 20, 9:12AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Amicus Therapeutics , a clinical-stage...
Amicus Therapeutics Has Returned 111.6% Since SmarTrend Recommendation (FOLD)
Comtex SmarTrend(R) - Wed Aug 20, 9:10AM CDT
SmarTrend identified an Uptrend for Amicus Therapeutics (NASDAQ:FOLD) on May 30th, 2014 at $2.42. In approximately 3 months, Amicus Therapeutics has returned 111.57% as of today's recent price of $5.12.
Yes, Call it a Comeback: Amicus Fabry Drug Posts Big Study Win
at The Street - Wed Aug 20, 5:01AM CDT
Based on the positive study results, Amicus intends to seek European approval for migalastat early next year.
Amicus Therapeutics Announces Positive Phase 3 Data From Fabry Monotherapy Study 012
GlobeNewswire - Wed Aug 20, 5:00AM CDT
Migalastat Successfully Meets Both Co-Primary Endpoints of Comparability to Enzyme Replacement Therapy (ERT) on Both Key Measures of Kidney Function
Pre-Market Review on Biotech Equities -- Exelixis, Novavax, Achillion Pharma, XOMA, and Amicus Therapeutics
PR Newswire - Wed Aug 13, 7:50AM CDT
On Tuesday, August 12, 2014, the NASDAQ Composite ended at 4,389.25, down 0.27%, the Dow Jones Industrial Average finished the session at 16,560.54, down 0.06% and the S&P 500 closed at 1,933.75, down 0.16%. During the trading session, seven out of ten sectors finished on a lower note. The S&P 500 Health Care Sector Index ended the day 0.14% lower at 699.06, and the index has declined 1.94% in the previous one month. Investor-Edge has initiated coverage on the following equities: Exelixis Inc. (NASDAQ: EXEL), Novavax Inc. (NASDAQ: NVAX), Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), XOMA Corp. (NASDAQ: XOMA), and Amicus Therapeutics Inc. (NASDAQ: FOLD). Free research on these five companies can be accessed at:
